Redeye comments on Cinclus Pharma’s announcement earlier today of a EUR220m licensing agreement with leading European pharmaceutical company Zentiva for the commercialization of linaprazan glurate in Europe. We view this as a strategically important milestone that not only provides immediate non-dilutive funding but also validates the long-term potential of the company’s lead asset. With Zentiva’s strong pan-European platform and growing focus on specialty medicines, we see this as a well-matched partnership that strengthens Cinclus’ commercial outlook.
LÄS MER
